

Public Health and Pharmacy Formulary Advisory Committee Meeting September 15, 2023 8:00AM

MEETING AGENDA

The committee will meet virtually.

Public Attendance by Phone: (503) 446-4951 Phone Conference ID: 558 628 256#

To sign up to provide public comment, email your request to pharmacy.formulary@bop.oregon.gov
by **10:00AM on 9/15/2023**

If you need accommodations under the Americans with Disabilities Act (ADA), complete and submit the online [OBOP Request for ADA Accommodations for Public Meetings form](#) located on our website.

Committee Members

- | | |
|---------------------------|----------------------|
| ➤ Lorinda Anderson, RPH | ➤ Andrew Gibler, RPH |
| ➤ Katherine Hammond, APRN | ➤ Sean Jones, MD |
| ➤ Elisha Lee, RPH | ➤ Mark Meyers, MD |
| ➤ Sarah Wickenhagen, APRN | |

OBOP Staff to Committee

- Jennifer Davis, RPH, Pharmacist Consultant
- Rachel Melvin, Operations Policy Analyst

Subject Matter Experts

- Amy Valdez, RPH Manager, Clinical Pharmacy Services, Kaiser
- Crystal Sharp, RPH Pharmacy Manager, Fred Meyer
- Grachelle Gonong, RPH, PGY1 Community-based Pharmacy Resident, Fred Meyer
- McKenzie Metcalf, Intern, PGY1 Community-based Pharmacy Resident, Fred Meyer
- Cierra Sitton, Intern, PGY1 Community-based Pharmacy Resident, Fred Meyer

Agenda Items

Welcome	<ul style="list-style-type: none"> ❖ OPEN SESSION – PUBLIC MAY ATTEND <li style="padding-left: 20px;">➤ Roll call <li style="padding-left: 20px;">➤ Housekeeping & Meeting Etiquette <li style="padding-left: 20px;">➤ Agenda review and approval <i>Action Necessary</i> <li style="padding-left: 20px;">➤ 8/16/2023 Meeting Summary review & approval <i>Action Necessary</i>
	<ul style="list-style-type: none"> ❖ Committee Protocol Development <li style="padding-left: 20px;">➤ Concept #1: Immunizations– <i>Davis</i> <ul style="list-style-type: none"> ▪ Cover Page/Treatment Pathway – 4th review ▪ Managing Adverse Reactions – 4th review ▪ Cholera- 3rd review ▪ COVID-19- 2nd review ▪ Hepatitis A &Twinrix- 2nd review ▪ Hepatitis B &Twinrix- 2nd review ▪ Hib - 3rd review ▪ HPV- 2nd review

	<ul style="list-style-type: none"> ▪ Influenza (IIV RIV 2023-24 - Interim)- 2nd review ▪ Influenza (LAIV 2023-24 - Interim) - 2nd review ▪ Japanese Encephalitis- 3rd review ▪ Meningococcal A, C, W, Y and B- 2nd review ▪ MMR/MMRV- 2nd review ▪ Pneumococcal Vaccines- 2nd review ▪ Polio/ Polio for Travelers- 3rd review ▪ Rabies (inactivated) - 3rd review ▪ RSV- 2nd review ▪ Td/Tdap- 2nd review ▪ Typhoid- 3rd review ▪ Varicella-containing vaccines- 2nd review ▪ Yellow fever - 3rd review ▪ Zoster-- 2nd review <ul style="list-style-type: none"> ❖ Formulary/Protocol Review <ul style="list-style-type: none"> ➤ Protocol Feedback – Continuation of Therapy ❖ Items to explore <ul style="list-style-type: none"> ➤ Idea #1: Doxycycline for STI Prevention (Doxy-PEP) ❖ Public Comment ❖ ADJOURN <i>Action Necessary</i>
<p>Upcoming Meeting Schedule <i>(subject to change)</i></p>	<ul style="list-style-type: none"> ❖ 2023 Virtual Meetings: <ul style="list-style-type: none"> ➤ 11/15/2023 ❖ 2024 Virtual Meetings: <ul style="list-style-type: none"> ➤ 2/21/2024, 5/15/2024, 8/21/2024, 11/20/2024

NOTE: The committee may rearrange its agenda to accommodate the committee or subject matter experts.

The Oregon Board of Pharmacy serves to promote and protect public health, safety, and welfare by ensuring high standards in the practice of pharmacy and through effective regulation of the manufacture and distribution of drugs.